Anitha B. Alex, Gerald W. Saunders, Alexandre Dalpé-Charron, Christopher A. Reilly, Karen S. Wilcox
Index: Neurotoxicology 32 , 392-399, (2011)
Full Text: HTML
Glutamate induced excitotoxic injury through over-activation of N-methyl-D-aspartate receptors (NMDARs) plays a critical role in the development of many neurodegenerative diseases. The present study was undertaken to evaluate the role of CGX-1007 (Conantokin G) as a neuroprotective agent against NMDA-induced excitotoxicity. Conantokin G, a cone snail peptide isolated from Conus geographus is reported to selectively inhibit NR2B containing NMDARs with high specificity and is shown to have potent anticonvulsant and antinociceptive effects. CGX-1007 significantly reduced the excitotoxic cell death induced by NMDA in organotypic hippocampal brain slice cultures in a concentration-dependent manner. In contrast, ifenprodil, another NR2B specific antagonist failed to offer neuroprotection against NMDA-induced excitotoxicity. We further determined that the neuroprotection observed is likely due to the action of CGX-1007 at multiple NMDA receptor subtypes. In a series of electrophysiology experiments, CGX-1007 inhibited NMDA-gated currents in human embryonic kidney (HEK) 293 cells expressing NMDA receptors containing either NR1a/NR2B or NR1a/NR2A subunit combinations. CGX-1007 produced a weak inhibition at NR1a/NR2C receptors, whereas it had no effect on NR1a/NR2D receptors. Further, the inhibition of NMDA receptors by CGX-1007 was voltage-dependent with greater inhibition seen at hyperpolarized membrane potentials. The voltage-dependence of CGX-1007 activity was also observed in recordings of NMDA-gated currents evoked in native receptors expressed in cortical neurons in culture. Based on our results, we conclude that CGX-1007 is a potent neuroprotective agent that acts as an antagonist at both NR2A and NR2B containing receptors.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Conantokin G
CAS:93438-65-4 |
C88H138N26O44 |
NMDA/NR2B selective antagonists in the treatment of ischemic...
2005-04-01 [Curr. Drug Targets. CNS Neurol. Disord. 4(2) , 143-51, (2005)] |
The effect of CGX-1007 and CI-1041, novel NMDA receptor anta...
2004-03-01 [Epilepsy Res. 59(1) , 13-24, (2004)] |
The selectivity of conantokin-G for ion channel inhibition o...
2009-08-01 [Neuropharmacology 57(2) , 127-36, (2009)] |
Conantokins inhibit NMDAR-dependent calcium influx in develo...
2010-10-01 [Mol. Cell. Neurosci. 45(2) , 163-72, (2010)] |
Blockade of hindbrain NMDA receptors containing NR2 subunits...
2009-04-01 [Am. J. Physiol. Regul. Integr. Comp. Physiol. 296(4) , R921-8, (2009)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved